Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections.
COVID-19
SARS-CoV-2
breadth
neutralization
variants
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
09
2021
accepted:
04
02
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus responsible for the Coronavirus Disease 2019 (COVID-19) pandemic. The emergence of variants of concern (VOCs) has become one of the most pressing issues in public health. To control VOCs, it is important to know which COVID-19 convalescent sera have cross-neutralizing activity against VOCs and how long the sera maintain this protective activity. Sera of patients infected with SARS-CoV-2 from March 2020 to January 2021 and admitted to Hyogo Prefectural Kakogawa Medical Center were selected. Blood was drawn from patients at 1-3, 3-6, and 6-8 months post onset. Then, a virus neutralization assay against SARS-CoV-2 variants (D614G mutation as conventional strain; B.1.1.7, P.1, and B.1.351 as VOCs) was performed using authentic viruses. We assessed 97 sera from 42 patients. Sera from 28 patients showed neutralizing activity that was sustained for 3-8 months post onset. The neutralizing antibody titer against D614G significantly decreased in sera of 6-8 months post onset compared to those of 1-3 months post onset. However, the neutralizing antibody titers against the three VOCs were not significantly different among 1-3, 3-6, and 6-8 months post onset. Our results indicate that neutralizing antibodies that recognize the common epitope for several variants may be maintained for a long time, while neutralizing antibodies having specific epitopes for a variant, produced in large quantities immediately after infection, may decrease quite rapidly.
Sections du résumé
Background
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus responsible for the Coronavirus Disease 2019 (COVID-19) pandemic. The emergence of variants of concern (VOCs) has become one of the most pressing issues in public health. To control VOCs, it is important to know which COVID-19 convalescent sera have cross-neutralizing activity against VOCs and how long the sera maintain this protective activity.
Methods
Sera of patients infected with SARS-CoV-2 from March 2020 to January 2021 and admitted to Hyogo Prefectural Kakogawa Medical Center were selected. Blood was drawn from patients at 1-3, 3-6, and 6-8 months post onset. Then, a virus neutralization assay against SARS-CoV-2 variants (D614G mutation as conventional strain; B.1.1.7, P.1, and B.1.351 as VOCs) was performed using authentic viruses.
Results
We assessed 97 sera from 42 patients. Sera from 28 patients showed neutralizing activity that was sustained for 3-8 months post onset. The neutralizing antibody titer against D614G significantly decreased in sera of 6-8 months post onset compared to those of 1-3 months post onset. However, the neutralizing antibody titers against the three VOCs were not significantly different among 1-3, 3-6, and 6-8 months post onset.
Discussion
Our results indicate that neutralizing antibodies that recognize the common epitope for several variants may be maintained for a long time, while neutralizing antibodies having specific epitopes for a variant, produced in large quantities immediately after infection, may decrease quite rapidly.
Identifiants
pubmed: 35281007
doi: 10.3389/fimmu.2022.773652
pmc: PMC8907139
doi:
Substances chimiques
Antibodies, Viral
0
Broadly Neutralizing Antibodies
0
Immunodominant Epitopes
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
773652Informations de copyright
Copyright © 2022 Kurahashi, Sutandhio, Furukawa, Tjan, Iwata, Sano, Tohma, Ohkita, Nakamura, Nishimura, Arii, Kiriu, Yamamoto, Nagano, Nishimura and Mori.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Nature. 2020 Sep;585(7824):174-177
pubmed: 32901123
JMA J. 2021 Jan 29;4(1):41-49
pubmed: 33575502
PLoS Negl Trop Dis. 2021 Jul 8;15(7):e0009551
pubmed: 34237072
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Sci Adv. 2021 Sep 03;7(36):eabj5365
pubmed: 34516917
Infect Genet Evol. 2021 Nov;95:105088
pubmed: 34560289
Front Immunol. 2021 Sep 23;12:751584
pubmed: 34630430
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Cell Host Microbe. 2021 Jul 14;29(7):1076-1092
pubmed: 34237248
JAMA. 2021 May 11;325(18):1896-1898
pubmed: 33739374
PLoS One. 2021 Jun 23;16(6):e0253487
pubmed: 34161386
Nat Microbiol. 2021 Nov;6(11):1433-1442
pubmed: 34654917
Cell. 2021 Jun 10;184(12):3086-3108
pubmed: 34087172
J Biomed Sci. 2020 Jan 2;27(1):1
pubmed: 31894001
J Med Virol. 2022 Apr;94(4):1641-1649
pubmed: 34914115
Clin Infect Dis. 2016 Jan 1;62(1):69-74
pubmed: 26261205
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Cell. 2021 Apr 1;184(7):1804-1820.e16
pubmed: 33691139
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
JMA J. 2021 Jan 29;4(1):1-7
pubmed: 33575497
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
Front Med (Lausanne). 2021 Apr 09;8:624924
pubmed: 33898477
Cochrane Database Syst Rev. 2021 May 20;5:CD013600
pubmed: 34013969
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Cell Rep. 2021 Jun 29;35(13):109320
pubmed: 34146478
Lancet. 2022 Jan 15;399(10321):234-236
pubmed: 34942101
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Sci Immunol. 2021 May 25;6(59):
pubmed: 34035118
Immunity. 2021 Aug 10;54(8):1841-1852.e4
pubmed: 34246326
Emerg Microbes Infect. 2022 Dec;11(1):1-5
pubmed: 34890524
Eur J Intern Med. 2021 Jul;89:87-96
pubmed: 34053848
Nat Commun. 2017 Nov 24;8(1):1781
pubmed: 29176567
J Infect Dis. 2021 Apr 8;223(7):1145-1149
pubmed: 33411935
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
Vaccines (Basel). 2021 May 06;9(5):
pubmed: 34066475
Nat Rev Drug Discov. 2020 Dec;19(12):827
pubmed: 33144717
Cell Host Microbe. 2021 Jul 14;29(7):1124-1136.e11
pubmed: 34171266
Nat Commun. 2021 Mar 22;12(1):1813
pubmed: 33753738
Transbound Emerg Dis. 2021 May 7;:
pubmed: 33960696
Clin Infect Dis. 2021 Sep 15;73(6):e1337-e1344
pubmed: 33851216
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Med (N Y). 2021 Mar 12;2(3):313-320.e4
pubmed: 33554155